Orr R M
CRC Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK.
Curr Opin Mol Ther. 2000 Apr;2(2):205-10.
Genetronics Inc has developed a MedPulser and a needle array applicator that delivers electric pulses to tumors and induces a transient permeabilization. Used in conjunction with intratumoral injections of anticancer drugs, this form of therapy, termed electroporation therapy, allows for intracellular accumulation of cytotoxic drugs without the toxic side effects associated with systemic administration. Accrual of preclinical data of electroporation therapy with bleomycin has led to clinical studies in patients with cutaneous and subcutaneous tumors. In 1999, objective responses were reported in a phase II study involving 30 patients with head and neck cancer with minimal side effects [328332]. Other indications for this form of treatment include liver and pancreatic cancers, Kaposi's sarcoma and melanoma [273388,290144]. Genetronics Inc and Ethicon Endo-Surgery (Johnson & Johnson Development Corp) are reviewing all clinical data from phase II studies prior to the initiation of a pivotal clinical trial in head and neck cancer.
基因电子公司已研发出一种MedPulser和一种针阵列施加器，可向肿瘤输送电脉冲并诱导瞬时通透性增加。这种治疗方式称为电穿孔疗法，与瘤内注射抗癌药物联合使用时，可使细胞毒性药物在细胞内蓄积，而无全身给药相关的毒副作用。博来霉素电穿孔疗法的临床前数据积累已促使针对皮肤和皮下肿瘤患者开展临床研究。1999年，一项涉及30例头颈部癌患者的II期研究报告了客观缓解，且副作用极小[328332]。这种治疗方式的其他适应症包括肝癌、胰腺癌、卡波西肉瘤和黑色素瘤[273388,290144]。在启动头颈部癌关键临床试验之前，基因电子公司和强生公司旗下的Ethicon Endo-Surgery正在审查II期研究的所有临床数据。
